DualityBio, BioNTech expand partnership to develop third ADC for solid tumours
BioNTech will obtain rights to commercialise the DB-1305 worldwide, except in Mainland China, Hong Kong Special Administrative Region…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Aug 23
BioNTech will obtain rights to commercialise the DB-1305 worldwide, except in Mainland China, Hong Kong Special Administrative Region…
08 Aug 23
According to the terms of the agreement, Astellas will invest $25m to buy 8,333,333 shares of common stock…
08 Aug 23
Under the terms of the agreement, Nautic will acquire Tabula Rasa for $10.50 in cash per share and…
PharmaceuticalsConsulting, Training and Other Pharmaceutical Services
08 Aug 23
IPAX-2 is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with external…
07 Aug 23
Zurzuvae causes central nervous system (CNS) depressant effects, and people who take the drug should not drive a…
07 Aug 23
Leveraging its extensive knowledge and capabilities in cell engineering, ultra-high-throughput multiplexed screening, protein characterisation, and process optimisation, Ginkgo…
04 Aug 23
In exchange for the exclusive global right to the TMPRSS6 siRNA programme, Alnylam will receive a $17.5m upfront…
04 Aug 23
The expanded agreement includes the renewal of the non-exclusive total laboratory solution collaboration agreement and an eco-social collaboration…
04 Aug 23
The partnership builds upon the companies' existing collaboration, which centres around the development and commercialisation of pelacarsen
04 Aug 23
Start-up US biotech company tackling rare diseases presents three case studies in France